GlassScriptPhysician profile
Harman Singh Kular
NPI 1003173550
$2,670.71
in general payments reported to CMS, 2019-2025
33 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.59 · 2020: $118 · 2021: $91.22 · 2022: $476 · 2023: $419 · 2024: $443 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $594.68 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $243.35 | 2022-2025 | Airsupra, Tezspire, Breztri |
| Mylan Specialty L.P. | $228.50 | 2019-2024 | Yupelri |
| Pulmonx Corporation | $161.06 | 2023 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Inspire Medical Systems, INC. | $147.87 | 2025 | Inspire |
| Mallinckrodt Hospital Products INC. | $146.87 | 2025 | Acthar |
| Baxter Healthcare | $118.48 | 2020 | |
| Insmed, INC. | $99.62 | 2024-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $96.27 | 2019-2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $80.67 | 2022-2024 | |
| Amgen INC. | $67.56 | 2022-2024 | Tezspire |
| Philips North America LLC | $67.34 | 2022-2025 | (2383) Sleepundivided, Vest Therapy Und, (Ak6) Vest Therapy |
| Pfizer INC. | $61.05 | 2023 | |
| Genzyme Corporation | $54.00 | 2025 | |
| Verona Pharma, INC. | $45.64 | 2025 | Ohtuvayre |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $42.14 | 2022-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $39.34 | 2025 | |
| Viatris Specialty LLC | $31.77 | 2025 | Yupelri |
| Vifor Pharma, INC. | $30.96 | 2024 | Veltassa |
| Harmony Biosciences LLC | $30.04 | 2023 | Wakix |
| Resmed Corp | $29.99 | 2023 | |
| Alcresta Therapeutics, INC. | $28.00 | 2024 | Relizorb |
| Avadel Cns Pharmaceuticals, LLC | $27.19 | 2025 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.27 | 2023 | Ofev |
| Electromed, INC. | $25.75 | 2022 | |
| United Therapeutics Corporation | $23.39 | 2021 | |
| Shionogi INC | $22.70 | 2023 | Fetroja |
| Actelion Pharmaceuticals US, INC. | $22.00 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $20.85 | 2025 | Neffy |
| Inogen, INC. | $15.16 | 2022 | |
| Abbott Laboratories | $14.93 | 2024 | Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $13.77 | 2024 | |
| Genentech USA, INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harman Kular listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.